Search Results
May 31, 2026, 21:30 ET LG Display to showcase world's largest Gaming OLED lineup in Taiwan
panel is the world's first to deliver ultra-high-definition 5K2K resolution. Combined with a 21:9 ultra-wide aspect ratio and a curvature of up to 1500R, it provides vivid and sharp picture quality, maximizing immersion in racing and simulation games.LG Display will also showcase RGB Stripe OLED,
More news about: LG Display
May 31, 2026, 21:06 ET 【直擊ASCO 2026】亞盛醫藥耐立克®治療CML-LBP與Ph+ BCP-ALL數據發佈，有望填補急變期治療空白
Jabbour教授表示：「復發/難治性Ph陽性ALL或CML淋系急變期患者的治療存在巨大的未滿足臨床需求。奧雷巴替尼聯合貝林妥歐單抗展現出令人鼓舞的活性和耐受性，凸顯了這一去化療新策略在此類難治性疾病中的潛力。」亞盛醫藥首席醫學官翟一帆博士表示：「此次快速口頭報告的研究首次在國際患者中驗證了耐立克®聯合貝林妥歐單抗針對CML-LBP與R/R Ph+ BCP-ALL的治療潛力。這兩個領域長期被視為BCR-ABL驅動血液腫瘤中『最難啃的骨頭』， 代表了預後最差、治療選擇最少的兩類終末階段。此次展示的數據非常令人鼓舞，有望填補急變期治療的長期空白。我們期待通過後
More news about: 亞盛醫藥
May 31, 2026, 20:48 ET Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
In addition, Hanmi will be eligible to receive royalties following product launch.About Hanmi Pharm. Co., Ltd. Hanmi is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology,
More news about: Hanmi Pharm. Co., Ltd.
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
patients, as well as mature Phase I data from longer follow-up in patients with advanced solid tumors. Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, commented, "As the clinical evidence continues to mature, CS2009 has advanced beyond early mechanistic validation
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026
PartnershipsFor chip design, MICROIP's "CATS Customized ASIC Technology and Solutions" integrates advanced AI EDA tools to assist R&D teams in shortening chip time-to-market by 6 to 9 months. At the event, MICROIP will offer a "Free ASIC Design Technical Consulting Service,"
More news about: MICROIP
May 31, 2026, 20:00 ET MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026
Ecosystem PartnershipsFor chip design, MICROIP's "CATS Customized ASIC Technology and Solutions" integrates advanced AI EDA tools to assist R&D teams in shortening chip time-to-market by 6 to 9 months. At the event, MICROIP will offer a "Free ASIC Design Technical Consulting Service," providing
More news about: MICROIP
May 31, 2026, 20:00 ET 마이크로아이피, 컴퓨텍스 2026에서 'AI 차량 시스템 비즈니스 그룹' 및 엣지 AI 혁신 기술 첫선
EDA 도구를 통합해 R&D 팀이 칩 출시 기간을 6~9개월 단축할 수 있도록 지원한다. 행사에서 마이크로아이피는 '무료 ASIC 설계 기술 컨설팅 서비스(Free ASIC Design Technical Consulting Service)'를 제공하며, 통합 가능성을 평가하기 위한 독점 PPA 최적화 분석을 실시할 예정이다.마이크로아이피는 엣지 AI 산업을 칩에서 현장 배포 단계로 발전시키기 위해 글로벌 생태계를 확장하고 있다. 마이크로아이피는 산업용 PC 선도 기업 AAEON과 협력해 RT-621R 랙마운트 섀시를 활용한
More news about: MICROIP
May 31, 2026, 20:00 ET 圖睿科技將於 COMPUTEX 2026 展出 AI-ready 全系列 RAID 儲存解決方案
加速儲存與資料保護解決方案領導者圖睿科技（Graid Technology）將於 COMPUTEX 2026 展出全系列 AI-ready RAID 儲存解決方案，涵蓋 GPU 伺服器、企業 AI、AI 資料中心、HPC 叢集、邊緣運算與企業資料中心等多元應用場景。圖睿科技將於 6 月 2 日至 5 日在台北南港展覽館二館 Booth R0502 展示完整產品組合，協助企業突破儲存瓶頸，將儲存轉化為 AI 基礎架構的效能加速器。
More news about: 圖睿科技
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned. Innovent and Takeda are co-developing IBI363 (Takeda R&D code: TAK-928) globally.SAN FRANCISCO and SUZHOU, China, May 31,
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
chemotherapy in the first-line treatment of advanced NSCLC (all PD-L1 expression levels)Innovent and Takeda are co-developing IBI363 (Takeda R&D code: TAK-928) globally.SAN FRANCISCO and SUZHOU, China, May 31,
More news about: Innovent Biologics
May 31, 2026, 20:00 ET Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders
dependability of Carbice pads will be a level-up for PC enthusiasts. We are excited to bring them to market and to collaborate with Carbice on future R&D."The NT-CP1 AM5/4 is validated for AMD Ryzen™ AM5 and AM4 processors. It carries the same vertically aligned carbon nanotube technology Carbice
More news about: Carbice Corporation
May 31, 2026, 19:30 ET TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at American Society of Clinical Oncology (ASCO) 2026.
More news about: TiumBio
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
a long-term vision, free of influence from fiduciary responsibilities. Servier invests close to 20% of revenue from brand-name medicines in R&D each year. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its
More news about: Servier Pharmaceuticals
May 31, 2026, 16:32 ET Creality Rayakan 12 Tahun Inovasi dengan KliTek™ dan Ekspansi Ekosistem Berbasis AI
baru dengan desain portabel dan kemampuan tangkapan digital (digital capture) yang sangat akurat.Sistem Daur Ulang Filamen M1 & R1 — platform daur ulang material yang membantu pengguna mengolah kembali limbah material menjadi filamen khusus, serta mendukung proses manufaktur
More news about: Creality
May 31, 2026, 14:09 ET EQT sets target fund size for EQT Infrastructure VII at EUR 21 billion
https://news.cision.com/eqt/r/eqt-sets-target-fund-size-for-eqt-infrastructure-vii-at-eur-21-billion,c4355536The following files are available for download:
More news about: EQT
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform,
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study includes five cohorts exploring RYBREVANT FASPRO™ across different treatment settings and regimens.Cohort 1 evaluated RYBREVANT FASPRO™ as monotherapy in patients with R/M HNSCC who had received prior platinum-based
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html 12 Napodano G, Ferro M, Sanseverino R. High-risk prostate cancer: A very challenging disease in the field of uro-oncology. Diagnostics (Basel). 202126;11(3):400. doi:10.3390/diagnostics11030400
More news about: Johnson & Johnson
May 31, 2026, 05:30 ET MARSTEK Unveils the New VENUS Family, Expanding Plug-in Batteries into a New Era of Home Energy Storage
MARSTEK as it continues accelerating the evolution of plug-in energy storage solutions for European households. Guests toured MARSTEK's Battery R&D Institute, R&D Center, Testing Laboratory, Experimental Center and production lines, including the VENUS E Gen 3.0 production line, inverter manufacturing
More news about: Marstek Energy Co., Limited
May 31, 2026, 05:30 ET MARSTEK dévoile la nouvelle gamme VENUS et fait entrer les batteries plug-in dans une nouvelle ère du stockage d'énergie résidentiel
l'entreprise continue d'accélérer l'évolution des solutions de stockage d'énergie plug‑in pour les foyers européens. Les invités ont visité le laboratoire de R&D sur les batteries, le laboratoire d'essais de fiabilité ainsi que les lignes de production automatisées de MARSTEK, dont la chaîne de production du
More news about: Marstek Energy Co., Limited
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
months.Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
by MSD.About Kelun-BiotechKelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major
More news about: Kelun-Biotech
May 30, 2026, 16:57 ET Creality đánh dấu cột mốc 12 năm với KliTek™ và mở rộng hệ sinh thái được hỗ trợ bởi AI
minh và khả năng thu nhận dữ liệu số có độ chính xác cao dành cho nhà sáng tạo và người dùng chuyên nghiệp.Hệ thống tái chế sợi nhựa M1 và R1 — Nền tảng tái chế và tái tạo vật liệu cho phép người dùng tái chế vật liệu thải và sản xuất sợi nhựa tùy chỉnh, hỗ trợ quy trình sản xuất bền vững
More news about: Creality
May 30, 2026, 16:52 ET 크리얼리티, KliTek™와 AI 기반 생태계 확장으로 12주년 맞아
레이저 플랫폼이다.Pika & Sermoon P1 Scanner — 휴대형 설계, 지능형 이미징, 고정밀 디지털 캡처 기능을 결합한 차세대 스캐닝 솔루션으로, 크리에이터와 전문 사용자를 위해 설계됐다.M1 & R1 Filament Recycling System — 사용자가 폐기 소재를 재활용하고 맞춤형 필라멘트를 생산할 수 있도록 하는 소재 재활용 및 재생 플랫폼으로, 더욱 지속 가능한 제조 워크플로를 지원한다.제품에서 완전한 AI 기반 생태계로
More news about: Creality
May 30, 2026, 15:15 ET EngineAI Resmikan Pabrik Cerdas di Shenzhen, Robot Humanoid T800 Mulai Dikirim secara Massal
massal, bergerak dari nol menuju skala penuh."Empat Pilar Strategis yang Menjaga KualitasDidukung kemampuan riset dan pengembangan (R&D) secara independen, EngineAI mengembangkan sistem penjaminan mutu yang bertumpu pada empat pilar utama:Kualitas rantai pasok
More news about: EngineAI